A new study now has identified a measurable indicator that could prove instrumental in the fight against HIV.
George Mason University's Yuntao Wu, focused on cofilin, a key protein that regulates cells to mobilise and fight against infection.
Click here to connect with us on WhatsApp
In an HIV-infected patient, cofilin dysfunction is a key factor in helper T cell defects, according to the research recently published in the journal Science Advances.
Helper T cells augment the body's immune response by recognising the presence of a foreign antigen and then helping the immune system mount a response.
Wu said, "When you have an infection, you need to mobilise the T cells," adding, "In HIV infection, there is a profound depletion of helper T cells in lymphoid tissues, such as those in the gut."
Wu and his team found that patients with HIV have "significantly lower" levels of cofilin phosphorylation--which provides a control of cofilin's activity with the addition of a phosphate--than healthy patients. Cofilin is a key protein that helps cells generate the driving force for migration. Proper cofilin phosphorylation is needed for cells to move in and out of tissues.
More From This Section
Their findings suggest that a lasting immune control to HIV isn't likely to come from antiretroviral therapy alone because it is not sufficient to repair the cofilin damage caused by HIV and to restore normal T cell migration in and out of tissues.
However, the researchers found that by stimulating the T cells with additional therapeutics, such as the α4β7 integrin antibody, they could modulate the levels of cofilin activity needed to restore T cell mobility.
The remedy has shown lasting effects in immune control of simian immunodeficiency virus (SIV), the simian form of the AIDS virus, in a monkey trial, but it has not showed the same results in HIV-infected human patients.
"Now we have a marker, and at least one target that we can focus on to discover new therapies to repair the immune damages for a functional cure," Wu said.
Disclaimer: No Business Standard Journalist was involved in creation of this content